XOMA Corporation (XOMA)
XOMA Corporation Revenue Growth: -36.74%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
XOMA Revenue Growth Rankings
| Overall | 3rd percentile | 4214 of 4362 |
| Sector | 8th percentile | 418 of 457 in Healthcare |
| Industry | 16th percentile | 105 of 126 in Biotechnology |
XOMA Revenue Growth Range, Past 5 Years
| Minimum | -81.86% | Mar 2010 |
| Maximum | 486.5% | Sep 2007 |
| Average | 58.97% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these XOMA related companies
XOMA News
$XOMA $TUMI $SPLK New Stock Ratings and Price Targets http://stks.co/3pgb
about 19 days ago by DrNick
about 19 days ago by DrNick
Canaccord Genuity Reiterates a 'Hold' on XOMA, Ltd. (XOMA); Phase 3 Uveitis Program Locked and Loaded
May 14, 9:42AM Street Insider
May 14, 9:42AM Street Insider
$XOMA on track to begin Phase 2 proof-of-concept study on erosive osteoarthritis&Phase 3 non-infectious Uveitis trial http://stks.co/3llP
about 24 days ago by DrNick
about 24 days ago by DrNick
Quant modell indicates a 2 - 1 chance for $XOMA not closing below 2.67 today. Now trading at 2.71 or -12.6%
about 25 days ago by TradeBot
about 25 days ago by TradeBot
XOMA Reports Financial Results for First Quarter 2012 and Highlights Recent Achievements
May 08, 4:05PM GlobeNewswire
May 08, 4:05PM GlobeNewswire
$XOMA KEY INFO - Xoma zeroes in on diabetes — and a partnership? http://stks.co/3iWf
about 26 days ago by DrNick
about 26 days ago by DrNick
$XOMA: KEY NEWS/INFO - "First to Invent" to "First to File" - AVI BioPharma and XOMA Look to Benefit http://stks.co/3iWP
about 26 days ago by DrNick
about 26 days ago by DrNick
$XOMA: KEY NEWS - XOMA Corp Acquires U.S. Rights To Perindopril Franchise
Tuesday, 17 Jan 2012
http://stks.co/3iWM
about 26 days ago by DrNick
about 26 days ago by DrNick
$XOMA ANALYST- OVERWEIGHT / BUY (WSJ) MEDIAN TARGET PRICE- $6.00 (WSJ) http://stks.co/3iUq
about 26 days ago by DrNick
about 26 days ago by DrNick
$XOMA http://stks.co/3gZw Continues higher. A strong run since March. Bullish signal on increased volume.
about 29 days ago by ACInvestorBlog
about 29 days ago by ACInvestorBlog
XOMA to Announce First Quarter 2012 Financial Results and Host Webcast on May 8
May 01, 9:00AM GlobeNewswire
May 01, 9:00AM GlobeNewswire
Canaccord Genuity Reiterates a 'Hold' on XOMA, Ltd. (XOMA); Q4/11: Gevokizumab Development Rolls On
Mar 15, 10:45AM Street Insider
Mar 15, 10:45AM Street Insider
XOMA (XOMA) Announces XMetA Study Demonstrates Potential to Improve Glycemic Control In Vivo
Mar 08, 8:04AM Street Insider
Mar 08, 8:04AM Street Insider
XOMA to Announce Fourth Quarter and Year-End 2011 Financial Results and Host Webcast Conference Call on March 14
Mar 07, 4:05PM GlobeNewswire
Mar 07, 4:05PM GlobeNewswire
XOMA Announces Pricing of $39.2 Million Public Offering of Common Stock and Warrants
Mar 06, 9:00AM Benzinga
Mar 06, 9:00AM Benzinga
Biotech Industry Rallies -- Arena Pharmaceuticals and XOMA Poised for Growth
Jan 31, 8:20AM Marketwire
Jan 31, 8:20AM Marketwire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| XOMA | 2.36 | -0.03 | -1.26% | 160.57M |
| XOM | 77.92 | -0.71 | -0.90% | 367.25B |
| XNY | 1.38 | -0.02 | -1.43% | 80.04M |
| XNPT | 5.38 | -0.50 | -8.50% | 191.69M |
| XMPT | 27.90 | -0.22 | -0.78% | |
| XME | 39.57 | +0.17 | +0.43% | |
| XLVS | 32.49 | -0.66 | -1.99% | |
| XLV | 35.51 | -0.64 | -1.77% | |
| XLUS | 29.04 | -0.17 | -0.56% | |
| XLU | 35.71 | -0.15 | -0.42% |
